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Abstract
ALS is a rapidly progressive, devastating neurodegenerative illness of adults that produces
disabling weakness and spasticity arising from death of lower and upper motor neurons. No
meaningful therapies exist to slow ALS progression, and molecular insights into pathogenesis and progression are sorely needed. In that context, we used high-depth, next generation
RNA sequencing (RNAseq, Illumina) to define gene network abnormalities in RNA samples
depleted of rRNA and isolated from cervical spinal cord sections of 7 ALS and 8 CTL samples. We aligned >50 million 2X150 bp paired-end sequences/sample to the hg19 human
genome and applied three different algorithms (Cuffdiff2, DEseq2, EdgeR) for identification
of differentially expressed genes (DEG’s). Ingenuity Pathways Analysis (IPA) and Weighted
Gene Co-expression Network Analysis (WGCNA) identified inflammatory processes as significantly elevated in our ALS samples, with tumor necrosis factor (TNF) found to be a major
pathway regulator (IPA) and TNFα-induced protein 2 (TNFAIP2) as a major network “hub”
gene (WGCNA). Using the oPOSSUM algorithm, we analyzed transcription factors (TF)
controlling expression of the nine DEG/hub genes in the ALS samples and identified TF’s
involved in inflammation (NFkB, REL, NFkB1) and macrophage function (NR1H2::RXRA
heterodimer). Transient expression in human iPSC-derived motor neurons of TNFAIP2
(also a DEG identified by all three algorithms) reduced cell viability and induced caspase 3/
7 activation. Using high-density RNAseq, multiple algorithms for DEG identification, and an
unsupervised gene co-expression network approach, we identified significant elevation of
inflammatory processes in ALS spinal cord with TNF as a major regulatory molecule. Overexpression of the DEG TNFAIP2 in human motor neurons, the population most vulnerable
to die in ALS, increased cell death and caspase 3/7 activation. We propose that therapies
targeted to reduce inflammatory TNFα signaling may be helpful in ALS patients.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a disease characterized by degeneration of upper and
lower motor neurons (MNs) in the brainstem and spinal cord. Average life expectancy after
diagnosis is between 2–5 years, and current treatment (riluzole) extends life by only a few
months.
~5% of ALS occurs in families (fALS), with 68% of European fALS cases explained by mutations in 9 loci (as of 2014). However, only 11% of European sporadic ALS (sALS) patients are
accounted for by mutations in these loci [1]. Sporadically occurring ALS (sALS) represents
~95% of all ALS cases [2] and is widely thought to have both polygenic and environmental contributions [3, 4]. “Agnostic” exploratory association studies have been adopted to elucidate the
genetic contributions to sALS [1, 5, 6].
Gene expression studies identify differentially expressed genes (DEG’s), which are genes
with statistically significantly changed expression values between groups. Over-representation
analyses can be used to infer their likely biological relevance. These analyses detect statistically
significant associations between an input list of genes compared to predefined groups of genes
known to influence various cellular processes
Heath et al [6] published a comprehensive review of ALS gene expression studies dating
back to 2001. Tissue types compared between ALS and control samples included: human
bicep, human lymphocytes, rodent gastrocnemius, human or rodent spinal tissue containing
disease-vulnerable MNs, and isolated spinal MNs. There was a broad range in the number (14
to 1,182) and identity of ALS group-specific DEG’s discovered in each study.
Interestingly, a recurrent set of associated cellular processes emerged across over-representation analyses using these sets of DEGs. These included oxidative stress, mitochondrial dysfunction, apoptosis, cytoskeletal architecture, inflammation, RNA processing, and protein
aggregation. Separate molecular biology assays revealed increased oxidative damage [7–11],
abnormal mitochondrial morphology [12–18], and elevated inflammation [19–33] in various
ALS tissues from human patients and fALS rodents. Increased inflammatory tumor necrosis
factor (TNF) signaling [28–33] in ALS tissues may have therapeutic relevance, as it known to
carry out cell fate decisions that may contribute to MN death [34]. Taken together, it is likely
aberrations in these processes contribute to ALS onset, progression, and symptoms.
Exploratory gene expression studies comparing disease and control groups allow us to form
novel hypotheses about what genes may functionally impact disease pathology. Candidate gene
selection for downstream molecular biology experiments is rarely trivial, as these high throughput experiments often yield considerable options. Commonly, researchers select a candidate
gene that 1) was identified as a DEG, 2) was in a group of DEG’s associated with cellular processes relevant to disease pathology, and 3) has known structural or functional properties plausibly connecting it to disease features.
Systems-level gene co-expression network analyses provide separate criteria for candidate
gene selection that can be used in conjunction with DEG analysis results. These analyses typically follow a step-wise process that involves 1) prediction of interconnected gene networks
using all samples’ gene expression measurements, 2) identification of networks statistically
associated with phenotypic traits (i.e. disease status), 3) over-representation analyses to identify
cellular processes associated with these networks, and 4) identification of highly connected
“hub” genes predicted to organize each prioritized network’s activity.
This approach has identified networks associated with a polygenic trait and plausibly related
cellular processes, and several of these networks’ hub genes were already associated with the
trait studied using separate molecular biology techniques [35, 36]. Arguably more compelling,
Horvath et al showed reducing expression of ASPM (a hub gene identified in a network
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associated with glioblastoma and mitosis) via siRNA significantly reduced proliferation rates in
glioblastoma tumor cells in vitro [37].
In this study, we gathered >50 million 2X150 RNA-Sequencing reads in 15 postmortem spinal section tissues (7 ALS patients and 8 neurologically healthy controls) to characterize transcriptome-wide gene expression differences specific to our ALS group. We aligned reads to the
hg19 reference genome using Bowtie2/Tophat2 [38]. We next performed three DEG analyses,
a weighted gene co-expression network analysis, over-representation analyses of prioritized
gene sets, and molecular assays testing a candidate hub gene’s potential to increase motor neuron death.
74 DEGs (56 up-regulated and 18 down-regulated) were identified in common across three
analyses (Cuffdiff2, EdgeR, and DeSeq2, [39–41]) at an FDR of 0.10. Our gene network analysis
(WGCNA, [42]) identified 37 different gene networks, and 2 were positively correlated with
disease status at a p-value <0.01. QIAGEN’s Ingenuity Pathway Analysis (IPA1, QIAGEN
Redwood City, www.qiagen.com/ingenuity), an over-representation analysis tool, revealed the
56 DEG’s up-regulated in the ALS group and genes comprising the gene network most strongly
correlated to disease status were both associated with numerous inflammatory processes. Additionally, tumor necrosis factor (TNF) was identified as an "activated" upstream regulator in
both gene groups. We prioritized this gene network for candidate gene selection, as 1) it was
associated with disease status and 2) inflammatory processes and TNF signaling were recurrently associated with ALS pathology in previous literature [19–33]
To identify “hub” genes, we used three WGCNA metrics calculated for every gene within
this network. We identified 12 “hub” genes (out of 495 total network genes) with scores in the
top quartile for all three metrics. 9 of these genes were separately identified as up-regulated
DEG’s in the ALS group across the three DEG analyses. TNFAIP2, a gene that encodes an
intracellular protein of the tumor necrosis factor family, was one of them.
Based on these findings and previous literature, we hypothesized TNFAIP2 functionally mediates motor neuron death via TNF signaling in motor neurons. To test this, we compared cell
viability and activated caspase 3/7 levels in human iPSC-derived motor neurons that overexpressed TNFAIP2-GFP or GFP for 24 hours. We show motor neurons that overexpressed
TNFAIP2-GFP had decreased cell viability and increased activated caspase 3/7 levels compared
to those overexpressing GFP alone. Taken together, these results suggest TNF signaling may play
an important role in ALS pathology and reducing its activity could be of therapeutic relevance.

Results
Sequencing Metrics
We collected >50 million 2X150 RNA-Sequencing reads per sample in 15 postmortem spinal
cord samples (7 ALS and 8 neurologically healthy controls). The following are averaged metrics
compiled using Picard’s CollectRNASeqMetrics (http://picard.sourceforge.net): 68,613,940
2X150 raw sequencing read pairs, 20,584,182,060 total sequencing bases, 65.62% of bases that
passed filter and aligned to the hg19 reference genome, 29.01% of aligned bases to rRNA/
tRNA/mitochondrial RNA species, 33.23% of aligned bases to mRNA species, and 37.76% of
aligned bases to intronic/intergenic species. Individual samples metrics can be found in S1 Fig.

Presence of known ALS mutations and SOD1 transcription
As of 2014, 11% of sALS in Caucasians were explained by causal mutations in 9 different loci.
Causal fALS mutations have been identified in at least 13 other genes, and may account for
additional sALS cases [1, 43]. Genome Analysis Toolkit (GATK, [44]) provides a bioinformatics pipeline (https://www.broadinstitute.org/gatk/guide/article?id=3891) that identifies
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sequencing variants in the form of single nucleotide variants (SNVs), insertions, and deletions
using input sequencing reads [44, 45].
We used GATK [46] to identify variants genome-wide in each of our ALS samples, then
extracted each sample’s variants located within the boundaries of the 21 genes in Fig 1 (S1–S7
Tables). We next assessed whether our ALS samples carried any of 471 “pathogenic” coding
variants previously identified in these 21 genes (S8 Table). We compiled this list of mutations
by gathering all coding (promoters, UTRs, and exons) variants classified as “pathogenic” in
relation to ALS in at least one of three separate databanks (the databank http://alsod.iop.kcl.ac.
uk/Statistics/pathogenicity.aspx referenced in [43], [47, 48].
Fig 1 lists genes with known causal ALS mutations, along with their chromosomal position
and number of "pathogenic" ALS variants reported in at least one of three databanks queried.
C9orf72 and HNRNPA2B1 only had "potentially" pathogenic variants listed, and ELP3 was
excluded, as it did not have any reported mutations in these databanks.
We discovered an ALS sample (ALS4) carried a “pathogenic” variant from this list. This variant is a missense mutation (A4V) in the superoxide dismutase 1 (SOD1) locus, and was found
in nearly half of ALS4’s sequencing reads (754/1576) aligning to SOD1. This likely suggests
there was no transcriptional preference for the wildtype or mutant DNA sequence. No other
pathogenic variants were found in ALS4 or the remaining ALS samples. None of these 21 genes
were differentially expressed between our patient and control samples.

Fig 1. Genes pathogenic when mutated for fALS.
doi:10.1371/journal.pone.0160520.g001
PLOS ONE | DOI:10.1371/journal.pone.0160520 August 3, 2016
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Differential Gene Expression Testing and Associated Cellular
Processes
We elected to identify ALS group-specific DEG’s using Cufflinks/Cuffdiff2, DESeq2, and
EdgeR. Each tool shows strengths and weaknesses in DEG calling that vary depending on
experimental conditions [49], so we ran all three to minimize biases. Samples averaged
18,750,634 paired-end reads uniquely assigned to known hg19 genes (excluding rRNA/tRNA/
mtRNA genes) for EdgeR and DESeq2 analyses (S2 Fig).
At an FDR of .10, Cuffdiff2 identified 425 DEG’s, DESeq2 identified 175 DEG’s, and EdgeR
identified 103 DEG’s (S9–S11 Tables). There were 74 DEG’s identified in common (56 upregulated and 18 downregulated) across all three analyses (Fig 2).

Weighted Gene Co-Expression Analysis (WGCNA) and the “Black”
Module”
We used WGCNA [42] to identify gene “modules”, or networks, from our dataset. This unsupervised technique identified 37 interconnected gene modules (arbitrarily assigned to different
colors) from a filtered list of 13,301 genes (Fig 3) without using 1) information about what
genes have been shown to interact in previous literature, or 2) information about which samples were cases or controls. Two of these modules (“black” and “sienna4”) were positively correlated with disease status at an uncorrected p-value < .01 (Fig 4).

Ingenuity Pathways Analysis (IPA1)
We next used QIAGEN’s Ingenuity Pathway Analysis (IPA1, QIAGEN Redwood City, www.
qiagen.com/ingenuity) to identify cellular processes and upstream regulators associated with
the up- and down- regulated DEG’s identified in our ALS samples relative to controls. Downregulated DEGs were associated with various cholesterol biosynthesis and inflammatory processes (S3 Fig).
Interestingly, the 56 up-regulated DEG’s were associated with multiple inflammatory processes (Fig 5), and tumor necrosis factor (TNF) was identified as a significant upstream
regulator.
Interestingly, IPA revealed the 495 genes comprising the module (S12 Table) most strongly
correlated to disease status (MEblack, R = 0.68, p = 0.006) were associated with inflammatory
processes and TNF was a predicted upstream regulator (Fig 5). As these IPA results were highly
similar to those for up-regulated DEGs in our ALS tissues, we next tested whether any of those
DEG’s were found in this module. Intriguingly, we found 64% (42/65) of our up-regulated
DEG’s were contained in this module (S4 Fig).
We decided to prioritize identified hub genes in this module for candidate gene selection.
We found it compelling that genes in this disease-associated module and our sALS-group specific up-regulated DEG’s shared associations to inflammatory processes and up-regulated TNF
signaling, despite discovery of both gene sets using independent exploratory approaches. These
findings are consistent with prior proposals that inflammatory processes and TNF signaling
play a role in ALS pathology [19–33].

WGCNA Hub Gene Identification
A user can identify module hub genes using either WGCNA’s “intramodular connectivity”
score or “modular membership” score calculated for every gene in a module of interest. The
intramodular connectivity score reflects the cumulative connection strength a given module
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Fig 2. Shown are lists of common DEGs identified as “upregulated” (left) and “downregulated” (right) in the ALS
group relative to controls across all three DEG analyses. Fold change values from Cuffdiff2 are listed.
doi:10.1371/journal.pone.0160520.g002
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gene has with all other module genes. The modular membership score reflects how representative that gene’s expression values are of the module as a whole.
Hub genes typically have large values for both of these metrics. To further prioritize one
hub gene over another, the authors of WGCNA [42] recommend using the “gene significance”
score. This score reflects how strongly a single gene’s expression values correlate with disease
status across samples.
12 genes in the “black” module had scores in the top quartile for intramodular connectivity,
modular membership, and gene significance metrics (S12 Table). 9 of these genes were separately identified as up-regulated DEG’s in the ALS group (Fig 6A). TNFAIP2, a gene encoding
an intracellular protein of the tumor necrosis factor family, was one of these nine. Fig 6B shows
all “black” module genes’ modular membership vs. gene significance scores, and TNFAIP2 is
highlighted in green (MM = 0.79, GS = 0.81).
We then sought to determine if the ALS hub gene/DEG group (Fig 6A) shared transcription
factors that control gene expression. We input these 9 hub/DEG genes into oPOSSUM-3 [50]
and after ranking by Z-score, found over-representation of TF’s mediating inflammation (REL;
Z = 3.33, NFkappaB; Z = 3.08, NFkB1; Z = 3.18) and macrophage function (NR1H2::RXRA;
Z = 3.33)

Selection of TNFAIP2
We selected TNFAIP2 as our candidate gene for molecular testing as a result of data-driven
findings in our study. First, TNFAIP2 belonged to the “black” module associated with ALS disease status, inflammatory processes, and TNF signaling. Second, TNFAIP2 was identified as
one of twelve module hub genes with scores in the top quartile for intramodular connectivity,
modular membership, and gene significance metrics. Third, TNFAIP2 was separately identified as an up-regulated DEG in our ALS samples using all three DEG-seeking algorithms.

Fig 3. Shown are all 13,301 genes (individual black lines at top) clustered by their topological overlap
dissimilarity scores. The multi-colored panel next to “Dynamic Tree Cut” shows 122 identified modules
using the Dynamic Tree Cut algorithm. The second multi-colored panel shows 37 larger modules identified
after highly correlated smaller modules were merged together.
doi:10.1371/journal.pone.0160520.g003
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Fig 4. Shown are each module eigengene’s correlation values with disease status, gender, and age.
The correlation score is listed above an associated p value.
doi:10.1371/journal.pone.0160520.g004

We also considered previous research findings. TNFAIP2 is an intracellular protein component of the exocyst, and a member of the tumor necrosis factor family. TNF signaling and
inflammation have long been suspected in ALS pathology [19–33]. To our knowledge,
TNFAIP2’s cellular functions in motor neurons have not been studied. TNFAIP2 is known to
increase in response to extracellular TNF [51–53], and has been separately associated with
increased apoptosis [54–56]. We hypothesized TNFAIP2 functionally mediates motor neuron
death via TNF signaling in motor neurons.

Molecular Testing of TNFAIP2
To test our hypothesis, we assessed cell viability and activated caspase 3/7 levels in human
motor neurons differentiated from induced pluripotential stem cells [57–59] that either 1)
overexpressed a plasmid encoding TNFAIP2 tagged with an C-terminal GFP (S5 Fig) or 2)
overexpressed the same plasmid encoding GFP alone (empty vector).
These motor neurons had a ~15–22 fold increase in expression of motor neuron specific
markers HB9 and ISL1 at day 21, suggesting successful differentiation (58). qPCR data (S13
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Fig 5. Select IPA Core Analysis Results are displayed for DEGs (56) identified as upregulated in the ALS group by all three analyses
(left) and genes (495) comprising the black module (right).
doi:10.1371/journal.pone.0160520.g005

Table) showed TNFAIP2 expression increased >300-fold in motor neurons transfected with
TNFAIP2-GFP relative to GFP alone.

PLOS ONE | DOI:10.1371/journal.pone.0160520 August 3, 2016
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Fig 6. 6A shows all black module hub genes and which was an upregulated DEG in the ALS group. 6B shows each
black module gene’s module membership vs. gene significance scores.
doi:10.1371/journal.pone.0160520.g006

The MTT cell viability assay showed motor neurons that overexpressed TNFAIP2-GFP
were significantly less viable, and a caspase 3/7 assay revealed these motor neurons had significantly increased levels of activated caspase 3/7 compared to motor neurons that overexpressed
GFP alone (Fig 7). Taken together, these results suggest overexpression of TNFAIP2 results in
motor neuron death, and may play a functional role in ALS pathology.

Fig 7. (left, “MTT”) shows absorbance readings reflecting MTT metabolism (a function viable cells perform) On day
21 of differentiation cells were transfected with TNFAIP2-GFP (TNFAIP2) vector or GFP alone vector (EV) and MTT
cell viability assay was performed 24 hrs later. Activated caspase 3/7 levels (right, “Casp 3/7 assay”) were measured
using fluorescently labeled antibodies. Day 21 motor neurons that overexpressed TNFAIP2-GFP (TNFAIP2)
compared to GFP alone (EV) were significantly less viable and have significantly more caspase 3/7 staining 24 hours
after introduction of the TNFAIP2 vector. Statistical analyses were carried out using unpaired t-tests and Prism1
software.
doi:10.1371/journal.pone.0160520.g007
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Discussion
sALS is a complex trait without a viable treatment, and its polygenic contributions remain
poorly understood. In this study, we combined deep RNA-sequencing, systems biology analyses, and molecular biology assays to elucidate ALS group-specific differences in postmortem
spinal tissue that may be relevant to disease pathology. To our knowledge, this is the only study
that exploits the benefits of next generation RNA-Sequencing [60, 61] to measure gene expression changes in postmortem cervical spinal tissue containing disease-vulnerable motor neurons
from sALS patients. We chose to study gene expression changes in human postmortem sALS
tissue over fALS rodent tissue, as recent findings suggest the majority of sALS cases do not
carry a known monogenic causal mutation [1] and this tissue is inaccessible at earlier stages of
the disease. The only other RNA-Sequencing study in human postmortem sALS tissues we are
aware of used cerebellar and prefrontal cortex tissues [62], and also found sALS-group specific
DEGs were associated with inflammatory processes.
Previous ALS studies have used gene network analyses to unveil disease-associated cellular
processes. Those using gene co-expression network analyses identified ALS tissue networks
associated with innate immune response, stress response, post-translational modifications,
inflammatory disease, and neurological disorders [63, 64]. Other ALS studies used gene network analyses that model gene-gene interactions using different criteria. These criteria include
only connecting genes with known interactions in previous literature, or using information
theoretics to eliminate indirect connections between genes inferred to be connected based on
the strength of their co-expression value alone. These studies identified ALS-specific networks
associated with organismal injury, immune response, post-translational modification, regulation of the actin cytoskeleton, and extracellular matrix repair [65, 66]. Ikiz et al applied the
MARINa algorithm to identify major regulators (such as transcription factors) within a gene
network identified in motor neurons in an in vitro ALS model characterized by MN death [67].
They identified 8 genes as drivers of motor neuron death including NFKB1, a pleiotropic transcription factor with important roles in innate immune response. Taken together, these findings support the use of systems-level gene network analyses to identify perturbed cellular
processes in ALS tissues, and hold potential to unveil therapeutic target genes.
In this study, we discovered only one of our ALS samples carried a known causal ALS mutation out of 471 mutations surveyed. We found inflammatory processes and TNF signaling
were significantly associated with sALS group-specific gene expression changes (IPA) using
independent exploratory DEG tests (Cuffdiff2, DESeq2, and EdgeR) and an unsupervised gene
network analysis (WGCNA). Finally, we demonstrated overexpression of the hub gene
TNFAIP2 in motor neurons differentiated from human iPSCs in vitro led to decreased cell viability and elevated levels of caspase 3/7, findings suggestive of increased cell death. Taken
together, these results corroborate previous reports that most instances of sALS have polygenic
contributions [1], and inflammatory TNF signaling plays an important role in sALS pathology
[19–33].
Modulating TNF signaling activity may be effective in slowing disease progression. TNF is a
potent inflammatory cytokine that plays an instrumental role in cell fate decisions. TNF-mediated pro-survival processes are largely effected via upregulation of the transcription factors
NFKB1 and JUN [68], whereas its cell death processes are ultimately carried out by initiator
and effector caspases. Bioactive forms of TNF commence these processes via two cell surface
receptors, TNFR1 and TNFR2. TNFR1 directs cell survival or death, whereas TNFR2 is only
known to promote pro-survival effects [34]. The extracellular domains of TNFR1 and TNFR2
are shed into general circulation after interacting with bioactive forms of TNF, and function in
a negative feedback loop as they retain their ability to bind TNF [69]. Intriguingly, elevated
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levels of TNF-alpha and extracellular domains of TNFR1 and TNFR2 have been found in the
blood [28] and serum [29, 30] of human ALS patients compared to controls.
We propose novel therapies to reduce TNF synthesis in human sALS patients, monitoring
blood levels of TNF and these extracellular TNFR domains as biomarkers throughout treatment. Two potential therapeutic agents are bupropion and curcumin. Bupropion, a drug commonly used to treat clinical depression, decreased TNF serum levels in mice likely via
increasing intracellular cAMP signaling after binding beta-adrenergic and/or D1 receptors
[70]. Curcumin, an anti-inflammatory compound in turmeric, reduced TNF transcription in
human cancer cells [71, 72] and lipopolysachharide (LPS)-stimulated murine microglia [73].
This likely occurs via inhibition of NFKB1, a transcription factor that is upregulated by TNF
signaling and known to induce TNF and other inflammatory cytokines [74]. Curcumin is also
predicted to bind and inhibit caspase-3 [75], an activator caspase with a known role in TNFmediated apoptosis. Curcumin oral bioavailability and brain penetration were substantially
increased by micellular formulation [76], setting the stage for clinical testing of it and bupropion separately and together to reduce TNFα signaling.
Thalidomide, a TNF synthesis inhibitor, has been reported in a Phase II trial to not alter
ALS progression[77]. However, the authors were unable with thalidomide to alter serum levels
of any cytokine, including TNF (see their Fig 6). These results suggest that the thalidomide
doses used, which were associated with side effects in some subjects, did not reduce TNF
synthesis.
Although we focused on TNFα signaling and modulated the hub gene TNFAIP2 in an ALSvulnerable cell type (human motor neurons) in our analyses, we do not claim aberrant inflammatory TNFα signaling as the sole factor in ALS pathogenesis. Downregulated DEGs in the
ALS group and genes in the other disease-associated module were associated with other cellular
processes (S3 and S6 Figs).
We also identified 8 hub genes that were upregulated DEGs within the “black” module that
was identified by WGCNA and was statistically associated with ALS. These genes are involved
in different gene families and could serve as foci for additional mechanistic studies and therapeutic interventions.
Genetic variants in APOE (Apoliprotein E), a gene encoding a protein important for transporting cholesterol and other lipids between cells, alter its function and are associated with an
accumulation of amyloid-Β peptides in the brain and an increased Alzheimer’s risk. These variants modify ALS age of onset and features of disease progression [78], warranting investigation
into whether aberrant expression of APOE could also influence ALS pathology.
BMF (Bcl2-modifying factor) binds to Bcl2 and related anti-apoptotic proteins and promotes apoptosis [79, 80]. Its expression is increased in human motor neurons exposed to
TNFα protein (data not shown), and could play an important role in motor neuron death.
CD37, a leukocyte-specific protein belonging to the tetraspanin superfamily, is integral to T
cell proliferation [81]. Aberrant expression of this gene may influence T cell activities during
innate immune responses implicated in ALS.
CXCL16 (Chemokine ligand 16), a transmembrane chemokine produced by reactive astroglial cells, is increased by TNFα [82] and induced by neurodegeneration. It promotes
CXCR6-positive glial cell invasion that favors astrogliosis [83], a feature seen in ALS CNS
tissues.
GPNMB (Glycoprotein NMB) was previously identified as an upregulated DEG in the spinal
cords of fALS rodents. Interestingly, extracellular fragments of GPNMB released by activated
astrocytes lessened the neurotoxicity of mutant SOD1, suggesting it may play protective role
against neurodegeneration [84].
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ITGAX (Integrin Alpha X), a leukocyte-specific integrin, was found as an upregulated DEG
in leukocytes that invaded the spinal cords of fALS rodents at different stages of disease progression [85]. ITGAX plays a known role in cell-cell interactions during immune responses,
warranting further research into its therapeutic potential in halting such processes that precede
neurodegeneration.
LILRB4 (Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4), a cell surface
receptor in immune cells, binds MHC class 1 molecules to inhibit immune responses. While
not directly studied in ALS tissues, LILRB4 expression negatively correlates with pathologic
inflammation in a mouse model of allergic pulmonary inflammation [86].
To our knowledge, no study has investigated the function of WDR91 (WD Repeat Domain
91), so it is impossible to speculate on its possible connection to ALS pathology.
Our study has several important limitations:
First, we examined a small number of postmortem cervical spinal cord sections for gene
expression. There are ~30,000 persons with ALS in the US. The cost of RNA-seq analysis limited the numbers of cases we could examine at the sequencing depth employed. As a result, it is
impossible to state to what degree our findings can be generalized to thousands of patients.
Second, we used postmortem tissue. As a result, we are examining gene expression of cells
(mainly astrocytes) that are “survivors” of the neurodegenerative process. To what extent ALS
modifies cellular gene expression over time is not known, and it is not possible presently to
examine human CNS tissues across disease progression. It is unclear whether the “young”
motor or other neurons produced by iPSC approaches will approximate changes seen in spinal
motorneurons present for many years as ALS progresses.
Third, RNA-Seq aligners have built-in biases that influence results in different ways, and
our alignments are subject to those conferred by Tophat2 and STAR (for the point mutation
analyses). Engstrom et al [87] compared alignment results from 26 mapping protocols on 4
common RNA-Seq datasets. Tophat2 reported a smaller number of alignments due to its low
tolerance for mismatches, but a higher number of splice sites when used with a guide annotation. STAR reported a larger number of primary alignments as it retains portions of a read
when unable to align the entire sequence, but also a greater number of false exon junctions. It
remains unclear which tools are best suited for different downstream analyses. As RNA-seq
technology continues to mature, future algorithms should improve in terms of these biases and
it will become more clear which tools are best to use for a given purpose.
Fourth, we did not yet explore novel transcripts, indels, or selective exon usage specific to
our sALS group in this dataset. We also wish to investigate expression of smaller non-coding
RNA’s, particularly microRNA’s, that regulate mRNA stability in a future study. We did find
substantial presence of mtDNA gene deletions with variable deletion burdens across mtDNAencoded respiratory genes (data not shown) that we will present in a subsequent paper.
We anticipate future exploratory sALS studies will continue to uncover polygenic contributions and identify potential therapeutic targets. Genome-wide Association Studies (GWAS)
comparing sALS cases vs. neurologically healthy controls were instrumental in the discovery of
excess pathogenic non-coding repeats in C9orf72 found in 7% of Caucasian sALS patients [1].
Chesi et al [5] identified excess de novo mutations in chromatin regulator genes using exome
sequencing, comparing sALS offspring with their neurologically healthy parents. This ALS
gene expression study joins those preceding it in identifying perturbed cellular processes and
corroborating them using separate molecular biology assays [1] [19–33]. Recent findings suggest considerable clinical heterogeneity between sALS patients [3, 88]. As sequencing costs
decrease, larger sample sizes conferring greater statistical detection power will become feasible.
These data sets will likely enable stratification of sALS by its varied molecular phenotypes as
has been seen in other diseases like breast cancer [89]. These approaches may ultimately lead
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to therapies against pathways that are universally beneficial to sALS patients, such as TNF signaling, as well as those specifically tailored to an individual patient’s pathophysiology.

Materials and Methods
Sample Demographics
Each sample’s age, ethnicity, and gender information can be found in S7 Fig. ALS Samples:
67.71 +/- 7.99 years of age, 7 Caucasian, 4 Male 3 Female. Control Samples: 69.75 +/- 11.29
years of age, 6 Caucasian 2 African American, 4 Male 4 Female.

Sample Preparation and Sequencing
Frozen cervical spinal cord specimens from all 15 samples were procured via the National Disease Research Interchange, Philadelphia, PA (http://www.ndri-resource.org) and stored at -80
degrees prior to usage. All samples were provided anonymously and were de-identified and
coded by number only. Total RNA was extracted from twenty 20-μm frozen cross sections cut
(at -20 degrees) using a Cryostat. We used the miRNeasy Mini (Qiagen) RNA extraction kit,
including the optional on-column DNAse step to prevent reads derived from DNA in downstream analysis. We further purified this RNA using the Qiagen RNeasy Micro kit to remove
organic contaminants.
RNA for all samples was quantified using a Nanodrop 2000c spectrophotometer (Thermo
Scientific) and quality was assessed using the Experion1 automated electrophoresis system
(Bio-Rad). Bio-Rad’s Experion1 calculated an RNA Quality Index (RQI) score via comparing
three portions of a sample’s electrophoretic profile to a manufactured standard of degraded
RNAs. RNA Quality Index (RQI) values range between 1–10, with increasing values representing higher quality RNA. 500 ng of RNA from each sample with an RQI score 7 was used for
library construction.
The Illumina Truseq Stranded Total RNA HT Sample Prep Kit 1 instructions were followed to generate barcoded RNA-Sequencing libraries for all eligible samples. We confirmed
libraries had the expected sized band (~260 bp) using the Experion automated electrophoresis
system (Bio-Rad). We then quantified libraries using the KAPA library quantification kit
(Kapa Biosystems, Wilmington, MA). Barcoded RNA-Sequencing libraries were equimolar
pooled and added to the Illumina Nextseq 500 lane for multiplex sequencing at Cofactor Genomics (Saint Louis, MO). Data was processed using the standard Illumina processing pipeline to
segregate each multiplexed sample’s reads, and raw fastq files for each sample were sent to us
for further processing.

Data Pre-Processing and Alignment with Tophat
FastQ files for each individual sample were input to FastQC (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/) for quality assessments. This software identifies any data
quality issues across metrics including: base quality per position across reads, overall GC content, sequence length distribution, and duplicate read frequency. All samples passed this QC
check (data not shown).
Samples were next processed using Trimmomatic [90]. Trimmomatic removed all Illumina
adaptor sequences and bases with a Phred quality score less than 20 from the 3’ end of our
reads. A Phred score of 20 indicates a 99% probability the base is correctly identified.
Fragments > or = to 50 bp were retained after that step. We took these filtering steps to ensure
high quality reads were used for alignment, as the average PHRED score in bases towards the
3’ end of reads across samples decreased (data not shown).
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We next used the Burrows-Wheeler Aligner (BWA, [91]) to calculate insert size metrics for
each sample (including average size and standard deviation) to improve Tophat2 alignment.
Once these metrics were obtained, we aligned each sample’s reads to the hg19 human reference
transcriptome then genome using Tophat2 [92]. The hg19 reference transcriptome and
genome were derived from Illumina iGenomes UCSC hg19 directory downloaded from the
Tophat webpage (https://ccb.jhu.edu/software/tophat/igenomes.shtml). Examples for these
commands can be found in S1 Note.

Calculation of Sequencing Alignment Metrics
We used Picard Tool’s (http://picard.sourceforge.net) CollectRNASeqMetrics command to
gather alignment data for each sample. We input each sample’s Tophat2 aligned reads file and
the “refFlat.txt.gz” file provided in the aforementioned Illumina iGenomes directory into each
command. We created a “ribosomal intervals file” containing rRNA, tRNA, and mitochondrial
RNA species as we wished to know how many reads aligned to these regions collectively. An
example of this command can be found in S1 Note.

Identification of sequencing variants in each sample
We downloaded STAR [93] and used it along with other necessary software (GATK, PicardTools) to complete the GATK pipeline (https://www.broadinstitute.org/gatk/guide/article?id=
3891) for identifying sequencing variants using RNA-Sequencing reads. The genome.fa file
from the aforementioned Illumina iGenomes directory was used along with each sample’s
Trimmomatic-processed fastq files for STAR alignment. We bypassed the optional indel
realignment step, and used default settings for all steps. We downloaded the dbsnp_138.hg19.
vcf (variant call file) for use in several commands from ftp://ftp.broadinstitute.org/bundle/2.8/
hg19/, as detailed on this GATK webpage (https://www.broadinstitute.org/gatk/guide/article?
id=1215).
We created a file containing all 21 fALS genes’ exon boundaries from the genes.gtf file in the
aforementioned Illumina iGenomes directory. We then excluded each sample’s variants discovered outside of these exon boundaries. We next checked whether any of the remaining variants corresponded to one of the “pathogenic” ALS mutations catalogued in at least one of three
databases queried (the databank http://alsod.iop.kcl.ac.uk/Statistics/pathogenicity.aspx referenced in [43, 47, 48]).
An example of the GATK pipeline commands used for each sample can be found in
S1 Note.

HTSeq count to produce individual sample count matrices for DeSeq2
and EdgeR
We next generated individual sample count matrices using HTSeq-Count [94] that reported
the number of aligned read pairs that uniquely map to known genes in the hg19 genome. We
used our Tophat2 mapped reads and the hg19 genes.gtf file provided in the aforementioned
Illumina igenomes directory to accomplish this. The counting procedure this software uses is
described on their website (http://www-huber.embl.de/users/anders/HTSeq/doc/count.html).
An example command for each sample can be found in S1 Note.

Cufflinks/Cuffdiff DEG Analysis
Gene and transcript abundances for all samples were estimated using Cufflinks v2.2.1 (http://
cufflinks.cbcb.umd.edu/howitworks.html, [39]). We opted to mask all rRNA, tRNA, and
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mitochondrial RNA mapped reads from FPKM calculations, as these RNA species accounted
for different proportions of total mapped reads in each sample (S1 Fig). We only considered
reads aligning to known genes (compatible hits norm flag) in our FPKM calculations, as we
suspected the number of novel transcripts varies across samples. We also used the genome bias
and multi-hits correction flags, as recommended by the Tuxedo Suite developers.
We used Cuffmerge to merge all samples’ transcripts.gtf files prior to running Cuffdiff2. We
then ran Cuffdiff2 to test for differential expression of known genes in the hg19 genome.
Again, we opted to use the genome bias and multi hits correction flags, and masked out all
rRNA, tRNA, and mitochondrial RNA mapped reads from for differential testing.
We calculated Benjamini-Hochberg corrected p-values using input Cuffdiff reported p-values for each gene via the R function p.adjust. We considered DEGs significant if their Benjamini-Hochberg corrected p-value was < 0.10. Examples of these commands are in S1 Note.

DESeq2 DEG Analysis
HTSeq count files for each sample were placed into a created DESeq2 directory prior to
DESeq2 [40] analysis in R.
We performed the DEG analysis using input HTSeq count matrices as prescribed in the
DESeq2 vignette. We considered DEG’s significant if their adjusted p values were < .10. These
commands are included in S1 Note.

EdgeR DEG Analysis
HTSeq count files for each sample were placed into a created EdgeR directory prior to EdgeR
[41] analysis in R. We then created a file containing all samples’ count information for all
genes prior to following the prescribed EdgeR analysis. We decided to filter out genes with a
cpm (counts per million) value <1 in 7 samples. We chose a cpm value of 1 as smaller values
more likely reflect noise. We chose 7 for our sample threshold as genes that were only
expressed in the disease or control group could play an important role in disease pathology.
We calculated Benjamini-Hochberg corrected p-values using EdgeR reported p-values for
each gene via the R function p.adjust. We considered DEG’s significant if their BenjaminiHochberg corrected p-value was < 0.10. Examples of these commands are in S1 Note.

Weighted Gene Co-Expression Network Identification and Association
Testing
WGCNA [42] follows a 6-step process to predict which genes are connected to each other, cluster them into gene networks, test which gene networks are associated with disease status, and
aid user selection of hub genes. The mathematical formulas used in each step are not included
in this description, but can be found in an earlier publication [95].
First, WGCNA calculates an “adjacency matrix” (a gene network) that reports a correlation
value between every pair of genes’ expression measurements across all 15 samples. An underlying assumption is the higher the correlation value between a pair of genes, the more likely it is
they are functionally connected. Once the adjacency matrix is constructed, summation of any
individual gene’s correlation values to all other genes reflects its level of overall connectedness.
Second, the adjacency matrix is raised to a software-determined exponential power, thereby
reducing noise by pushing weaker pairwise connection values closer to zero relative to stronger
values. The exponential power used is the lowest value needed to ensure the network approximates scale-free topology. In this context, scale-free topology is satisfied when a small number
of genes (hub genes) are highly connected to other genes, whereas the majority of genes are
weakly connected to other genes. Many biological (including gene co-expression) networks
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demonstrate scale-free topology [95], and their network functions are more likely disrupted by
specifically targeting highly connected members [96, 97]. This step lays the foundation for
identification of hub genes within smaller modules (networks) of interest later in this analysis.
Third, the adjacency matrix is transformed into a “topological overlap” matrix by calculating topological overlap (TOM) scores for each gene. This score accounts for each pair of genes’
connection strength (adjacency value) to each other as well as their connection strengths (adjacency values) to every other gene in the adjacency matrix. Higher TOM scores indicate a pair
of genes is more likely connected to each other and a shared set of other genes.
Fourth, WGCNA identifies gene co-expression networks via average linkage hierarchical
clustering using a TOM-based dissimilarity measure (1-TOM score for every gene) as a measure of distance. The resultant dendrogram of clustered genes is segregated into individual
modules with at least 30 genes using WGCNA’s dynamic tree-cutting algorithm [42].
Fifth, WGCNA calculates each module’s “eigengene”, or first principle component, using all
samples’ gene expression values for all genes in that module. A module eigengene is considered
a summarized expression profile representative of that module for all samples. Each module
eigengene is then correlated against every other module eigengene. If two or more modules’
eigengenes have a correlation value >.75, those modules are merged together generating a
larger module. Module eigengenes are re-calculated at this stage and the process is repeated
until there are no module eigengenes that correlate to each other with a value >.75.
Finally, each module eigengene is tested for statistical association to user-provided continuous or binary phenotypic traits, including disease status. Correlation test p-values based on the
student test are reported, and are equivalent to a Wald test in a linear regression.

Weighted Gene Co-Expression Network Analysis
We first generated a filtered list of 13,301 genes and their Cufflinks FPKM values for all samples to analyze in WGCNA. All of these genes had an FPKM value >2 in at least 7 samples. We
chose an FPKM of 2 as smaller values more likely reflect noise. We chose 7 for our sample
threshold as genes that are only expressed in the disease or control group could play an important role in disease pathology. We log-transformed these FPKM values using log2 (FPKM
value +1) as recommended on the WGCNA FAQ’s page (http://labs.genetics.ucla.edu/horvath/
CoexpressionNetwork/Rpackages/WGCNA/faq.html) prior to analysis.
Our analysis was guided by steps 1, 2b, and 3 in the R Tutorial listed under “I. Network analysis of liver expression data from female mice: finding modules related to body weight” from
their website (http://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/
WGCNA/Tutorials/).
We deviated from the tutorial several times. We generated a “signed weighted” adjacency
matrix for downstream analyses as opposed to the default “unsigned weighted” network. We
chose this option to preserve the direction of a pair of genes’ correlation, as a positive correlation may indicate “activation” whereas a negative correlation may indicate “repression”. The
unsigned networks do not preserve the direction of correlation. We used the “bicor” (biweight
midcorrelation) correlation in place of the pearson correlation to construct our adjacency
matrix and determine the exponential value necessary to approximate scale-free topology (S8
Fig).
We chose this option as we had a small sample size, and biweight midcorrelations are more
robust to outliers compared to pearson correlations [42]. We added the flag “corOptions = list
(maxPOutliers = 0.1))” to further reduce outlier effects.
Commands used after loading the sample data expression matrix (S14 Table) and phenotypic data (S15 Table) as instructed in part 1 of the tutorial are detailed in S1 Note.
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iPSC generation and Neural Induction
Integration-free iPSCs were generated from peripheral blood mononuclear cells (MNC) from a
healthy male donor, aged 62, using a previously described protocol [57], with modifications
[59]. Briefly, the pEB-C5 and pEB-Tg plasmids (Addgene) were electroporated into cells using
an Amaxa Nucleofector 4D system (Lonza, Allendale, NJ). After three weeks, viable colonies
were expanded in mTeSR medium on Geltrex (Life Technologies) coated plates. Neuralization
of iPSCs was accomplished using PSC Neural Induction Medium (Life Technologies) according to the protocol with modifications [58]. All cultures were maintained at 37°C in a humidified CO2 incubator with the oxygen level held at 5%.

Motor Neuron Differentiation
After neural induction, iPSCs were differentiated as described previously [58], with some modifications [59]. Briefly, adherent cells were grown in neural induction media containing
DMEM/F12 with 0.2 μM LDN-193189 (LDN; Stemgent), 10 μM SB431542 (SB; Stemgent), 10
ng/ml BDNF (R&D systems), 0.4 ug/ml L-ascorbic acid (Sigma), 2 mM GlutaMAX-I supplement, 1% N-2 supplement, and 1% nonessential amino acids (NEAA). Two days later 1 μM
RA was added. On day four LDN/SB was stopped and 1 μM smoothened agonist (SAG; Calbiochem or Santa Cruz) and 0.5 μM PM were added. On day 14 cells were switched to neurobasal
media containing 2 mM GlutaMAX-I, 2% B-27, 1% NEAA, 0.4 ug/ml AA, 10 ng/ml GDNF
(R&D), 10 ng/ml CNTF (R&D). Media was replaced every 2–3 days. Unless otherwise specified, all cell culture materials were purchased from Life Technologies. All cultures were grown
at 37°C in 5% oxygen and 5% CO2 conditions.

MTT/Caspase 3/7 Assays
On day 21 of differentiation cells were transfected with TNFAIP2 plasmid or empty vector control (Origene) using FuGENE HD Transfection Reagent (Promega). For transfection, 100 ng
plasmid DNA was added per well of a 96-well plate and the Fugene:DNA ratio was 4:1. After
24 hours of treatment, cell viability was measured using the In Vitro Toxicology Assay Kit,
MTT based (Sigma, TOX1) according to manufacturer instructions. For detection of activated
caspase 3/7, the FLICA1 660 Caspase 3/7 Assay Kit (ImmunoChemistry Technologies) was
used according to manufacturer instructions. For quantification, cells were fixed and 5–10 representative fields were taken with an Olympus FV1000 confocal microscope. Images were analyzed using MetaMorph image analysis software (Molecular Devices) and pixel intensity was
normalized to the number of cells per image, identified by DAPI nuclear staining.

Real-time quantitative PCR (qPCR)
For qPCR analysis, RNA was extracted with the RNeasy Plus Micro Kit (Qiagen) according to
manufacturer instructions. Quantification of isolated RNA was performed using a Nanodrop
2000c spectrophotometer (Thermo Scientific). RNA was reverse transcribed into cDNA using
the iScript cDNA synthesis kit (BioRad). For qPCR, 50 ng cDNA per well was loaded into a
96-well plate and analyzed with the CFX96 Real Time PCR Detection System (BioRad). All
samples were analyzed in triplicate. Data was normalized to the geometric mean of two reference genes determined to have the greatest stability using the software qbasePLUS-GeNorm
(BioGazelle; 14.3.3.Z and CYC1). Primer sets are available upon request. Statistics were calculated using unpaired t-test in Prism software (GraphPad, Prism). Error bars represent standard
error of the mean.
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Supporting Information
S1 Fig. Sample metrics collected using Picard’s CollectRNASeqMetrics command.
PF = Passed Filter.
(PDF)
S2 Fig. Shown are the number of paired end reads that aligned either uniquely or multiply
to hg19 genes. Uniquely aligned reads were used for DeSeq2 and EdgeR analyses.
(PDF)
S3 Fig. Shown are IPA Core Analysis Results for DEGs (18) identified as downregulated in
the ALS group by all three analyses.
(PDF)
S4 Fig. Shown are DEGs identified as “upregulated” in the ALS group that were also found
in the black module. Fold change values from Cuffdiff2 are listed.
(PDF)
S5 Fig. Shown is the TNFAIP2-GFP plasmid used in this experiment. The empty vector
used for the EV group was the same plasmid with TNFAIP2 CDS taken out.
(PDF)
S6 Fig. Shown are IPA Core Analysis Results for the 67 genes comprising the sienna4 module defined by the WGCNA analysis.
(PDF)
S7 Fig. Individual ages, genders and ethnicities for the subjects from whom the cervical spinal cord samples used in this study were obtained. ALS = amyotrophic lateral sclerosis;
CTL = control.
(PDF)
S8 Fig. Shown are the effects on Scale Independence and Mean Connectivity of raising the
adjacency matrix to the power of 24. The results approximate scale free topology at .80 correlation. Data are derived from the WGCNA analyses.
(PDF)
S1 Note. Pre-Processing and Alignment Commands (Unix).
(PDF)
S1 Table. GATK analysis of tissue sample ALS1.
(XLS)
S2 Table. GATK analysis of tissue sample ALS2.
(XLS)
S3 Table. GATK analysis of tissue sample ALS3.
(XLS)
S4 Table. GATK analysis of tissue sample ALS4.
(XLS)
S5 Table. GATK analysis of tissue sample ALS9.
(XLS)
S6 Table. GATK analysis of tissue sample ALS10.
(XLS)
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S7 Table. GATK analysis of tissue sample ALS14.
(XLS)
S8 Table. Pathogenic coding variants known in ALS.
(XLSX)
S9 Table. DEG's determined by Cuffdiff algorithm.
(XLS)
S10 Table. DEG's determined by DESeq2 algorithm.
(XLS)
S11 Table. DEG's determined by EdgeR algorithm.
(XLS)
S12 Table. "Black module" genes and their properties as determined by WGCNA.
(XLSX)
S13 Table. qPCR results for TNFAIP2 expression in both motor neuron groups.
(XLSX)
S14 Table. All Samples' log-transformed FPKM values for select genes.
(XLS)
S15 Table. Sample Phenotypic Data for WGCNA association testing.
(XLS)
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